Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT06173596 Completed - Healthy Clinical Trials

A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to determine the effect of multiple doses of itraconazole on the single dose PK of ALXN2080, to determine the effect of multiple doses of fluconazole on the single dose PK of ALXN2080 (optional), and to determine the effect of multiple doses of carbamazepine on the single dose PK of ALXN2080.

NCT ID: NCT06173414 Completed - Healthy Clinical Trials

Adaptive Optics ScanningLaser Ophthalmoscope Safety and Efficacy Clinical Trial

Start date: July 5, 2023
Phase:
Study type: Observational

This prospective, multicenter, single-group, target-value clinical trial was designed to evaluate the efficacy and safety of an Adaptive Optics ScanningLaser Ophthalmoscope(AOSLO) for ophthalmic examination.

NCT ID: NCT06166992 Completed - Healthy Clinical Trials

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).

NCT ID: NCT06166251 Completed - Healthy Clinical Trials

The Effects of Exercise Timing and Intensity on Motor Learning in Healthy Adults.

Start date: June 12, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to compare of the effects of a single session of aerobic exercise with different intensity and timing on motor learning processes in healthy young adults.

NCT ID: NCT06165146 Completed - Healthy Clinical Trials

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Start date: November 10, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days.

NCT ID: NCT06164652 Completed - Healthy Clinical Trials

Evaluation of the Validity of the Ceriter Stride One in Measuring Gait and Pressure Parameters in Healthy Adults

CSO-validity
Start date: November 30, 2023
Phase: N/A
Study type: Interventional

The Ceriter Stride One is a certified medical device that aims to provide a better, more independent and safe gait pattern for people with neurological disorders, such as Parkinson's disease. The Stride One detects the (abnormal) gait pattern via an insole with pressure sensors and generates customised audio feedback (app), e.g. to avoid or correct Freezing or Gait (Parkinson's). To gain more insight into the accuracy of the pressure and gait recordings, we want to compare them with those of the GAITRite. The GAITRite is an electronic walking carpet with an active zone 7.32m long and 0.61m wide. The carpet has pressure sensors embedded in horizontal lines. When a person steps on the carpet, these sensors capture the pressure distribution which, with the help of an algorithm, allows the collection of parameters per time unit (including speed, step time, stride time, cadence, etc.) and space (step and stride length, step and stride width, etc.). The GAITrite is considered a gold standard for capturing temporal and spatial data related to gait pattern. Our research question can be answered by having healthy subjects step over the GAITRite with the Ceriter Stride One on, and then checking the agreement between spatiotemporal factors. Thus, after IC and recording of administrative data, healthy adults will be invited for this cross-sectional validity study of a pressure-sensitive insole (Ceriter Stride One) against the validated and reliable gold standard, the GaitRite. At intake, the informed consent is gone over and signed. The inclusion and exclusion criteria are then questioned in a short interview. Inclusion criteria are pain-free and safe walking. Exclusion criteria are pregnancy and (congenital or acquired) orthopaedic, neurological and other defects that make walking without a walking aid or orthosis (or shoe adaptation) painful, difficult and/or unsafe, Ceriter insoles are placed in the test subjects' shoes, if possible in place of their own insoles, in case of orthotics on top. Via a Bluetooth transmitter, the captured signals from the pressure sensors are transmitted to and mobile phone and then via the internet to Ceriter's data portal where they are further processed and, for the purpose of this study, made available to the researchers.Subjects then step on the walking carpet with sensors (GAITRite) with these insoles in their shoes.Both systems record the pressures and analyse the gait pattern from there. Each test subject is expected to step across the walking carpet at a comfortable pace for three full lengths and 3 lengths involving acceleration. This, fitted with the insoles, so that sufficient steps are available to average out step parameters. The aim of the study is thus to find out to what extent the spatiotemporal parameters captured with the Ceriter Stride One coincide with those of the GaitRite.

NCT ID: NCT06161090 Completed - Healthy Clinical Trials

Study of CM310 in Healthy Subjects

Start date: September 3, 2019
Phase: Phase 1
Study type: Interventional

This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.

NCT ID: NCT06160414 Completed - Healthy Clinical Trials

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Start date: December 7, 2023
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to determine the effect of multiple doses of ALXN2080 on the single-dose PK of rosuvastatin and to determine the effect of multiple doses of ALXN2080 on the single-dose PK of metformin.

NCT ID: NCT06160141 Completed - Healthy Clinical Trials

Effect of Two Years of Resistance Training in Cardiac Function in Older Women: a Randomized Controlled Trial

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Purpose: This study aimed to determine the effect of 48 weeks of resistance training (RT) on cardiac function in older women. Methods: Sixty-four older women (≥ 60 years), physically independent, were selected for this study. Participants were randomized into a training group (TG, n = 33) and a control group (CG, n = 31). The RT program was conducted over 48 weeks, three sessions a week, on nonconsecutive days, in the morning hours. Participants performed eight exercises for the whole body (chest press, horizontal leg press, seated row, leg extension, triceps pushdown, lying leg curl, preacher curl, seated calf raise) in three sets of 8-12 repetitions. The echocardiography was performed according to current guidelines before and after 48 weeks by an experienced echocardiographer blinded to patient status and group assignment. One-repetition maximum (1-RM) tests were used to analyze muscular strength. Glusoce, lipid profile, and C-reactive protein were measured. DEXA was used to measure body fat and muscle mass.

NCT ID: NCT06153329 Completed - Healthy Clinical Trials

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

Start date: June 17, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, single-dose, open-label, positive-controlled, randomized, three-cycle, crossover 8-hour euglycemic clamp study to evaluate the PK, PD, safety and tolerability of THDB0206 injection after subcutaneous injection in healthy Chinese subjects. This trial will enroll 39 subjects to receive the investigational medicinal products.